National Institute of Cancer Research, National Health Research Institutes, 2 F, No, 367, Sheng Li Road, Tainan 70456, Taiwan.
BMC Cancer. 2014 Feb 18;14:102. doi: 10.1186/1471-2407-14-102.
To investigate the incidence of gastrointestinal stromal tumors (GISTs) in Taiwan and the impact of imatinib on the overall survival (OS) of GIST patients.
GISTs were identified from the Taiwan Cancer Registry (TCR) from 1998 to 2008. The age-adjusted incidence rates and the observed OS rates were calculated. Cox proportional hazards models were applied to examine the mortality risk in three time periods (1998-2001, 2002-2004, 2005-2008) according to the application and availability of imatinib.
From 1998 to 2008, 2,986 GISTs were diagnosed in Taiwan. The incidence increased from 1.13 per 100,000 in 1998 to 1.97 per 100,000 in 2008. The most common sites were stomach (47-59%), small intestine (31-38%), and colon/rectum (6-9%). The 5-year observed OS was 66.5% (60.3% for men, 74.2% for women, P < .0001). GISTs in the stomach had a better 5-year observed OS (69.4%) than those in the small intestine (65.1%) (P < .0001). The outcome of GIST improved significantly after the more widespread use of imatinib; the 5-year observed OS increased from 58.9% during 1998-2001 to 70.2% during 2005-2008 (P < .0001). Younger age, female sex, stomach location, and later diagnostic years were independent predictors of a better survival.
The incidence of GIST has been increasing in Taiwan, partially due to the advancement of diagnostic technology/method and the increased awareness by physicians. The outcome of GIST has improved significantly with the availability and the wider use of imatinib.
研究台湾地区胃肠道间质瘤（GIST）的发病率，以及伊马替尼对 GIST 患者总生存期（OS）的影响。
从 1998 年至 2008 年，通过台湾癌症登记处（TCR）确定 GIST 病例。计算年龄校正发病率和观察到的 OS 率。应用 Cox 比例风险模型，根据伊马替尼的应用和可及性，分别在三个时间段（1998-2001 年、2002-2004 年、2005-2008 年）检查死亡率风险。
1998 年至 2008 年，台湾共诊断出 2986 例 GIST。发病率从 1998 年的每 100,000 人 1.13 例上升至 2008 年的每 100,000 人 1.97 例。最常见的部位是胃（47-59%）、小肠（31-38%）和结肠/直肠（6-9%）。5 年观察到的 OS 为 66.5%（男性为 60.3%，女性为 74.2%，P<0.0001）。胃 GIST 的 5 年观察到的 OS（69.4%）优于小肠 GIST（65.1%）（P<0.0001）。随着伊马替尼的广泛应用，GIST 的结果显著改善；5 年观察到的 OS 从 1998-2001 年的 58.9%增加到 2005-2008 年的 70.2%（P<0.0001）。年龄较小、女性、胃部位和较晚的诊断年份是生存更好的独立预测因素。
台湾 GIST 的发病率一直在上升，部分原因是诊断技术/方法的进步和医生意识的提高。随着伊马替尼的可用性和更广泛的应用，GIST 的结果显著改善。
